The pharmaceutical industry is making remarkable progress in its quest for decarbonisation, with emissions already on a significant decline. Yet, the journey to Net Zero remains fraught with challenges, particularly in curbing Scope 3 emissions within the workplace. Now more than ever, it is crucial for industry partners to drive improvements that support this global goal.
Pharmaceutical companies are uniquely aware of the interconnected health of people and the planet. As early signatories to the UN’s Race to Zero campaign, these companies have swiftly calculated their carbon footprints, set science-based targets, and invested heavily in decarbonisation initiatives. Leading businesses like AstraZeneca have achieved notable results, halving their Scope 1 and 2 greenhouse gas emissions in seven years, and investing $1 billion in the Ambition Zero Carbon programme to tackle Scope 3 emissions throughout their value chain.
Tackling Scope 1 and 2 emissions...
